Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Chk1 and 14-3-3 proteins inhibit atypical E2Fs to prevent a permanent cell cycle arrest.

Yuan R, Vos HR, van Es RM, Chen J, Burgering BM, Westendorp B, de Bruin A.

EMBO J. 2018 Mar 1;37(5). pii: e97877. doi: 10.15252/embj.201797877. Epub 2018 Jan 23.

2.

DYRK1A Is a Regulator of S-Phase Entry in Hepatic Progenitor Cells.

Kruitwagen HS, Westendorp B, Viebahn CS, Post K, van Wolferen ME, Oosterhoff LA, Egan DA, Delabar JM, Toussaint MJ, Schotanus BA, de Bruin A, Rothuizen J, Penning LC, Spee B.

Stem Cells Dev. 2018 Jan 15;27(2):133-146. doi: 10.1089/scd.2017.0139. Epub 2018 Jan 3.

PMID:
29179659
3.

Dosage-dependent copy number gains in E2f1 and E2f3 drive hepatocellular carcinoma.

Kent LN, Bae S, Tsai SY, Tang X, Srivastava A, Koivisto C, Martin CK, Ridolfi E, Miller GC, Zorko SM, Plevris E, Hadjiyannis Y, Perez M, Nolan E, Kladney R, Westendorp B, de Bruin A, Fernandez S, Rosol TJ, Pohar KS, Pipas JM, Leone G.

J Clin Invest. 2017 Mar 1;127(3):830-842. doi: 10.1172/JCI87583. Epub 2017 Jan 30.

4.

E2f8 mediates tumor suppression in postnatal liver development.

Kent LN, Rakijas JB, Pandit SK, Westendorp B, Chen HZ, Huntington JT, Tang X, Bae S, Srivastava A, Senapati S, Koivisto C, Martin CK, Cuitino MC, Perez M, Clouse JM, Chokshi V, Shinde N, Kladney R, Sun D, Perez-Castro A, Matondo RB, Nantasanti S, Mokry M, Huang K, Machiraju R, Fernandez S, Rosol TJ, Coppola V, Pohar KS, Pipas JM, Schmidt CR, de Bruin A, Leone G.

J Clin Invest. 2016 Aug 1;126(8):2955-69. doi: 10.1172/JCI85506. Epub 2016 Jul 25.

5.

Feedback regulation between atypical E2Fs and APC/CCdh1 coordinates cell cycle progression.

Boekhout M, Yuan R, Wondergem AP, Segeren HA, van Liere EA, Awol N, Jansen I, Wolthuis RM, de Bruin A, Westendorp B.

EMBO Rep. 2016 Mar;17(3):414-27. doi: 10.15252/embr.201540984. Epub 2016 Feb 5.

6.

Physiological significance of polyploidization in mammalian cells.

Pandit SK, Westendorp B, de Bruin A.

Trends Cell Biol. 2013 Nov;23(11):556-66. doi: 10.1016/j.tcb.2013.06.002. Epub 2013 Jul 10. Review.

PMID:
23849927
7.

HIF proteins connect the RB-E2F factors to angiogenesis.

Bakker WJ, Weijts BG, Westendorp B, de Bruin A.

Transcription. 2013 Mar-Apr;4(2):62-6. doi: 10.4161/trns.23680. Epub 2013 Feb 14.

8.

E2F8 is essential for polyploidization in mammalian cells.

Pandit SK, Westendorp B, Nantasanti S, van Liere E, Tooten PC, Cornelissen PW, Toussaint MJ, Lamers WH, de Bruin A.

Nat Cell Biol. 2012 Nov;14(11):1181-91. doi: 10.1038/ncb2585. Epub 2012 Oct 14.

PMID:
23064264
9.

E2F7 and E2F8 promote angiogenesis through transcriptional activation of VEGFA in cooperation with HIF1.

Weijts BG, Bakker WJ, Cornelissen PW, Liang KH, Schaftenaar FH, Westendorp B, de Wolf CA, Paciejewska M, Scheele CL, Kent L, Leone G, Schulte-Merker S, de Bruin A.

EMBO J. 2012 Oct 3;31(19):3871-84. doi: 10.1038/emboj.2012.231. Epub 2012 Aug 17.

10.

The E2F6 repressor activates gene expression in myocardium resulting in dilated cardiomyopathy.

Westendorp B, Major JL, Nader M, Salih M, Leenen FH, Tuana BS.

FASEB J. 2012 Jun;26(6):2569-79. doi: 10.1096/fj.11-203174. Epub 2012 Mar 7.

PMID:
22403008
11.

Tail-anchored membrane protein SLMAP is a novel regulator of cardiac function at the sarcoplasmic reticulum.

Nader M, Westendorp B, Hawari O, Salih M, Stewart AF, Leenen FH, Tuana BS.

Am J Physiol Heart Circ Physiol. 2012 Mar 1;302(5):H1138-45. doi: 10.1152/ajpheart.00872.2011. Epub 2011 Dec 16.

12.

E2F7 represses a network of oscillating cell cycle genes to control S-phase progression.

Westendorp B, Mokry M, Groot Koerkamp MJ, Holstege FC, Cuppen E, de Bruin A.

Nucleic Acids Res. 2012 Apr;40(8):3511-23. doi: 10.1093/nar/gkr1203. Epub 2011 Dec 17.

13.

Adverse renal effects of hydrochlorothiazide in rats with myocardial infarction treated with an ACE inhibitor.

Westendorp B, Hamming I, Szymanski MK, Navis G, van Goor H, Buikema H, van Gilst WH, Schoemaker RG.

Eur J Pharmacol. 2009 Jan 14;602(2-3):373-9. doi: 10.1016/j.ejphar.2008.11.055. Epub 2008 Dec 3.

PMID:
19084001
14.

Beneficial effects of add-on hydrochlorothiazide in rats with myocardial infarction optimally treated with quinapril.

Westendorp B, Schoemaker RG, Buikema H, de Zeeuw D, Boomsma F, van Gilst WH, van Veldhuisen DJ.

Eur J Heart Fail. 2005 Dec;7(7):1085-94.

15.

Hydrochlorothiazide increases plasma or tissue angiotensin-converting enzyme-inhibitor drug levels in rats with myocardial infarction: differential effects on lisinopril and zofenopril.

Westendorp B, Schoemaker RG, van Gilst WH, van Veldhuisen DJ, Buikema H.

Eur J Pharmacol. 2005 Dec 19;527(1-3):141-9. Epub 2005 Nov 28.

PMID:
16310764
16.

Improvement of EDHF by chronic ACE inhibition declines rapidly after withdrawal in rats with myocardial infarction.

Westendorp B, Schoemaker RG, van Gilst WH, Buikema H.

J Cardiovasc Pharmacol. 2005 Dec;46(6):766-72.

PMID:
16306800
17.

Progressive left ventricular hypertrophy after withdrawal of long-term ACE inhibition following experimental myocardial infarction.

Westendorp B, Schoemaker RG, Buikema H, Boomsma F, van Veldhuisen DJ, van Gilst WH.

Eur J Heart Fail. 2006 Mar;8(2):122-30. Epub 2005 Aug 5.

18.

Dietary sodium restriction specifically potentiates left ventricular ACE inhibition by zofenopril, and is associated with attenuated hypertrophic response in rats with myocardial infarction.

Westendorp B, Schoemaker RG, Buikema H, de Zeeuw D, van Veldhuisen DJ, van Gilst WH.

J Renin Angiotensin Aldosterone Syst. 2004 Mar;5(1):27-32.

PMID:
15136971

Supplemental Content

Loading ...
Support Center